Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 2/20 | 0.65 |
| ▸ | JAK2 | O60674 | 14/20 | 0.64 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.53 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801271 | 0.92 | JAK2 (0.61) | PLK4JAK2JAK3MAPK8MAPK10 | |
| SCHEMBL12801089 | 0.90 | JAK2 (0.61) | PLK4JAK2SMG1JAK3MAPK8 | |
| SCHEMBL12274670 | 0.87 | JAK2 (0.63) | PLK4JAK2SMG1JAK3MAPK8 | |
| SCHEMBL12801263 | 0.84 | JAK2 (0.71) | PLK4JAK2JAK3MAPK8MAPK10 | |
| SCHEMBL12801110 | 0.84 | JAK2 (0.66) | PLK4JAK2SMG1JAK3MAPK8 | |
| SCHEMBL12801273 | 0.83 | JAK2 (0.78) | PLK4JAK2SMG1JAK3MAPK8 | |
| SCHEMBL12800920 | 0.82 | JAK2 (0.68) | PLK4JAK2JAK3MAPK8MAPK10 | |
| SCHEMBL12801702 | 0.81 | JAK2 (0.64) | JAK2JAK3MAPK8MAPK10MYLK4 | |
| SCHEMBL12801620 | 0.81 | JAK2 (0.66) | JAK2JAK3 | |
| SCHEMBL12801098 | 0.80 | JAK2 (0.76) | JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |